# Concert Pharmaceuticals Inc. (CNCE)

Source: https://www.quantisnow.com/company/CNCE
Generated: 2026-11-21T09:40:36.518Z

- Ticker: CNCE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- Website: concertpharma.com

## About

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

## Latest CNCE news and filings

- 2023-03-16 13:00 UTC [SEC Form 15-12G filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-concert-pharmaceuticals-inc-4210760)
- 2023-03-14 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-concert-pharmaceuticals-inc-4196072)
- 2023-03-14 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-concert-pharmaceuticals-inc-4196053)
- 2023-03-14 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-concert-pharmaceuticals-inc-4196017)
- 2023-03-14 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-concert-pharmaceuticals-inc-4196005)
- 2023-02-24 21:04 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by Concert Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-concert-pharmaceuticals-inc-amendment-4116524)
- 2023-02-24 21:02 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Concert Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-concert-pharmaceuticals-inc-amendment-4116447)
- 2023-02-16 13:51 UTC [SEC Form 4] [SEC Form 4: Stuart Nancy sold $50,380 worth of shares (6,048 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 262,596 units (withholding obligation)](https://www.quantisnow.com/insight/sec-form-4-stuart-nancy-sold-50380-worth-of-shares-4075852)
- 2023-02-16 13:49 UTC [SEC Form 4] [SEC Form 4: Munsie Jeffrey A sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 88,049 units to cover withholding tax](https://www.quantisnow.com/insight/sec-form-4-munsie-jeffrey-a-sold-31375-worth-of-4075842)
- 2023-02-16 13:48 UTC [SEC Form 4] [SEC Form 4: Cassella James V sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 173,061 units to satisfy withholding obligation](https://www.quantisnow.com/insight/sec-form-4-cassella-james-v-sold-31375-worth-of-4075833)
- 2023-02-16 13:47 UTC [SEC Form 4] [SEC Form 4: Becker Marc A. sold $31,337 worth of shares (3,762 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 123,863 units (for tax liability)](https://www.quantisnow.com/insight/sec-form-4-becker-marc-a-sold-31337-worth-of-4075827)
- 2023-02-15 12:28 UTC [Market Chatter] [Concert Pharmaceuticals Says FDA Determined That Deuruxolitinib Will Maintain Its Breakthrough Therapy Designation](https://www.quantisnow.com/insight/concert-pharmaceuticals-says-fda-determined-that-deuruxolitinib-will-maintain-its-4068028)
- 2023-02-15 12:00 UTC [Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata](https://www.quantisnow.com/insight/concert-pharmaceuticals-maintains-deuruxolitinib-breakthrough-therapy-designation-from-fda-for-4067798)
- 2023-02-14 21:45 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-concert-pharmaceuticals-inc-amendment-4064738)
- 2023-02-14 19:35 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-concert-pharmaceuticals-inc-amendment-4061488)
- 2023-02-13 14:25 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-concert-pharmaceuticals-inc-4046294)
- 2023-02-10 20:51 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-concert-pharmaceuticals-inc-4041141)
- 2023-02-02 13:11 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9 filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc-14d9-filed-by-concert-pharmaceuticals-inc-3992636)
- 2023-02-02 12:31 UTC [SEC Schedule TOT] [SEC Form SC TO-T filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc-to-t-filed-by-concert-pharmaceuticals-inc-3992226)
- 2023-02-01 22:12 UTC [SEC Form SC TO-C filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc-to-c-filed-by-concert-pharmaceuticals-inc-3990345)
- 2023-01-31 22:19 UTC [SEC Form SC TO-C filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc-to-c-filed-by-concert-pharmaceuticals-inc-3982639)
- 2023-01-31 13:30 UTC [SEC Form 4] [SEC Form 4: Stuart Nancy sold $110,220 worth of shares (13,200 units at $8.35) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 268,644 units (withholding tax)](https://www.quantisnow.com/insight/sec-form-4-stuart-nancy-sold-110220-worth-of-shares-3977444)
- 2023-01-31 13:29 UTC [SEC Form 4] [SEC Form 4: Munsie Jeffrey A sold $70,917 worth of shares (8,493 units at $8.35) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 91,811 units (for withholding tax)](https://www.quantisnow.com/insight/sec-form-4-munsie-jeffrey-a-sold-70917-worth-of-3977394)
- 2023-01-31 13:28 UTC [SEC Form 4] [SEC Form 4: Cassella James V sold $84,385 worth of shares (10,106 units at $8.35) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 176,823 units (withholding tax)](https://www.quantisnow.com/insight/sec-form-4-cassella-james-v-sold-84385-worth-of-3977346)
- 2023-01-31 13:27 UTC [SEC Form 4] [SEC Form 4: Becker Marc A. sold $70,917 worth of shares (8,493 units at $8.35) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 127,625 units (for withholding tax)](https://www.quantisnow.com/insight/sec-form-4-becker-marc-a-sold-70917-worth-of-3977337)
- 2023-01-20 15:20 UTC [Market Insight] [JonesTrading Downgrades Concert Pharma to Hold](https://www.quantisnow.com/insight/jonestrading-downgrades-concert-pharma-to-hold-3933720)
- 2023-01-19 22:25 UTC [SEC Form SC14D9C filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc14d9c-filed-by-concert-pharmaceuticals-inc-3931412)
- 2023-01-19 22:17 UTC [SEC Form SC TO-C filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc-to-c-filed-by-concert-pharmaceuticals-inc-3931337)
- 2023-01-19 18:33 UTC [Market Insight] [Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session](https://www.quantisnow.com/insight/why-jupiter-wellness-shares-are-trading-lower-by-around-40-3929713)
- 2023-01-19 17:30 UTC [Market Insight] [12 Health Care Stocks Moving In Thursday's Intraday Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-thursdays-intraday-session-3929413)
- 2023-01-19 15:37 UTC [Market Insight] [Concert Pharmaceuticals, Coeur Mining And Other Big Stocks Moving Higher On Thursday](https://www.quantisnow.com/insight/concert-pharmaceuticals-coeur-mining-and-other-big-stocks-moving-higher-3928803)
- 2023-01-19 15:13 UTC [Market Insight] [Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low](https://www.quantisnow.com/insight/dow-falls-200-points-jobless-claims-drop-to-4-month-low-3928693)
- 2023-01-19 14:39 UTC [Dividends] [Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata](https://www.quantisnow.com/insight/sun-pharma-to-acquire-concert-pharmaceuticals-advancing-the-potential-treatment-3928444)
- 2023-01-19 14:26 UTC [SEC Form SC14D9C filed by Concert Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc14d9c-filed-by-concert-pharmaceuticals-inc-3928365)
- 2023-01-19 14:23 UTC [SEC Form 8-K] [Concert Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/concert-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-3928352)
- 2023-01-19 14:15 UTC [Market Insight] [India-Based Sun Pharma Scoops Up Concert Pharmaceuticals For $576M Plus Milestones](https://www.quantisnow.com/insight/india-based-sun-pharma-scoops-up-concert-pharmaceuticals-for-576m-plus-3928302)
- 2023-01-19 13:41 UTC [Market Chatter] [Concert Pharmaceuticals shares are trading higher after Sun Pharma announced it will acquire the company.](https://www.quantisnow.com/insight/concert-pharmaceuticals-shares-are-trading-higher-after-sun-pharma-announced-3927833)
- 2023-01-19 13:33 UTC [Market Insight] [Concert Pharmaceuticals Shares Resume Trade](https://www.quantisnow.com/insight/concert-pharmaceuticals-shares-resume-trade-3927782)
- 2023-01-19 13:05 UTC [Market Chatter] [Concert Pharmaceuticals, Inc. Shares To Resume Trade At 8:30 a.m. ET](https://www.quantisnow.com/insight/concert-pharmaceuticals-inc-shares-to-resume-trade-at-830-am-3927513)
- 2023-01-19 13:02 UTC [Market Chatter] [Sun Pharma To Acquire Concert Pharmaceuticals For $8/Share, Plus A Contingent Value Right For Up To $3.50/Share Of Common Stock On Achievement Of Certain Time-based Net Sales Milestones](https://www.quantisnow.com/insight/sun-pharma-to-acquire-concert-pharmaceuticals-for-8share-plus-a-3927467)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CNCE
- Earnings history: https://www.quantisnow.com/earnings/CNCE
- Dividend history: https://www.quantisnow.com/dividends/CNCE
- Insider transactions: https://www.quantisnow.com/insiders/CNCE
- Options chain: https://www.quantisnow.com/options/CNCE
- SEC 8-K filings only: https://www.quantisnow.com/company/CNCE/8-k
- RSS and alerts for CNCE: https://www.quantisnow.com/docs/rss-feeds.md
